Neuroregeneration
Regrow neurons, connections, and brain tissue — honestly, where the science is
The goal is to regrow what the brain loses — new neurons, new connections, repaired circuits, restored support cells — turning the oldest rule in neurology, that the brain cannot regenerate, into something the science is slowly, honestly disproving. This is the steepest frontier in the Healthy pillar, and the page maps the whole of it: each pathway, who is building it, and exactly where its evidence stands.
For most of medical history, the rule was that the brain cannot regenerate. That rule turned out to be not quite absolute — but close enough that brain regeneration remains the steepest challenge in regenerative medicine. The human brain makes some new neurons in specific regions, though even that has been debated by scientists for three decades. Beyond that narrow natural capacity, regrowing the brain means rebuilding many distinct things — neurons, the connections between them, the circuits they form, and the support cells that keep them alive — each its own scientific frontier with its own researchers and trials. The honest picture: the brain cannot meaningfully regrow itself in people today, but the science of changing that is real, varied, and advancing.
We are building toward genuine neuroregeneration across its full breadth — and on this page, every pathway names the specific science behind it: who is doing the work, what the evidence shows, and what stage it has truly reached.
Each pathway — with the science and the people behind it
Protecting what remains Demonstrated — clinical
Because regrowth is so hard, preventing loss first — see neuroprotection — remains the most powerful tool we have. The work: the Lancet standing Commission on Dementia (2024) established that ~45% of dementia is preventable; the FINGER / World-Wide FINGERS network tests it across populations. An engaged, enriched life — including human connection — supports the healthy brain environment regeneration depends on.
Supporting natural neurogenesis Clinical
The adult human brain appears to make some new neurons in the hippocampus across life — supported by activity and BDNF, and by a healthy brain environment fed by sleep, brain energy, and low chronic stress. The evidence: human dentate-gyrus studies (published in the Journal of Neuroscience) found new-neuron formation persisting into the 10th decade of life, with marked impairment in Alzheimer’s; one estimate puts it near 700 new neurons a day. Its extent in humans is still genuinely debated.
Understanding the neurogenic niche Clinical
Regeneration starts from the brain’s own stem-cell reservoirs (the dentate gyrus and ventricular-subventricular zone). The work: a 2025 review (Simard, Matosin & Mechawar) maps the three-decade scientific debate and the next-generation sequencing methods now used to measure the niche — foundational to every pathway below.
Driving plasticity-based repair Demonstrated — clinical
Where neurons cannot be replaced, the brain rewires surviving circuits to recover function. The work: the established rehabilitation and neuroplasticity evidence base (funded largely by the National Institute of Neurological Disorders and Stroke (NINDS, NIH)), the same science behind cognitive restoration.
Repairing synapses Clinical / Frontier
Much brain loss is loss of synapses — the connections between neurons — before whole cells die. Why it matters: restoring synaptic density is a distinct target central to recovery in injury and disease. The evidence: the brain forms new synapses through its own experience-driven plasticity — enriched, stimulating environments have been shown to increase synapse density by up to 25%, and neurons near an injury can form new synapses to compensate for what was lost.
Regenerating support cells (glia & myelin) Clinical / Frontier
The brain’s glial cells — including myelin-making oligodendrocytes — regenerate more readily than neurons. The trial: the Cambridge Centre for Myelin Repair’s CCMR-Two study (reported at ECTRIMS 2025, 67 people with MS) showed that myelin repair can be promoted in living people — early human evidence on a major part of the problem.
Cell reprogramming (glia to neurons) Frontier
A frontier approach guides the brain’s own glial cells to become new neurons in place — using the brain’s own existing cells. The science: direct lineage reprogramming via neuron-defining transcription factors, an active laboratory frontier (recent in-vivo work, 2025). Not yet a human therapy, and we say so plainly.
Rebuilding neural circuits Frontier
Growing a neuron is not enough — new neurons must integrate into working circuits. The honest hard problem: newly formed neurons often fail to functionally integrate and reconstruct circuits, and glial scars can impede repair. This integration challenge is the true measure of whether regeneration restores anything. Frontier.
Guiding repair with biomaterials Frontier
Engineered scaffolds and 3D-bioprinted matrices can guide the brain’s regenerating cells across damaged tissue. The work: regenerative-bioengineering research developing bioengineered scaffolds and bioprinted platforms to support the brain’s own repair, in preclinical and earliest research work.
Restoring function, not just cells Clinical / Frontier
The point is functional: regeneration succeeds only when it restores ability. The benchmark: research shows the brain recovers lost function through its own cortical remapping — generating new circuits that route around damaged areas and restore ability, driven by axonal sprouting and synaptic remodeling. This functional readout — genuine recovered ability, not just new cells — is the honest north star of the whole field.
Cited as evidence the capability is real — not as partners or endorsers.
Prevention science
The Lancet standing Commission on Dementia (2024) and the FINGER / World-Wide FINGERS network — establishing that preventing loss is the most powerful tool while regeneration matures (mechanism 1).
Neurogenesis researchers
Academic neuroscience groups studying adult human hippocampal neurogenesis and the neurogenic niche, including the decades-long debate over its extent (mechanisms 2–3).
In-place reprogramming researchers
Labs advancing direct conversion of the brain’s own glial cells into new neurons in place — using the brain’s existing cells, an active 2025 laboratory frontier (mechanism 7).
Cell-reprogramming labs
Research groups converting glial cells directly into neurons in place via transcription-factor reprogramming — a fast-moving laboratory frontier (mechanism 8).
Regenerative-engineering groups
Biomaterial, scaffold, and 3D-bioprinting researchers in regenerative bioengineering, working on guided CNS repair (mechanisms 9–10).
Public funding & enabling science
the National Institute of Neurological Disorders and Stroke (NINDS, NIH) and the National Institute on Aging (NIA, NIH) fund the span from neurogenesis to in-place regeneration. Enabling fields: adult-neurogenesis research · neuroplasticity · endogenous neural stem-cell biology · direct cell reprogramming · synaptic-repair science · regenerative biomaterials.
The technologies span a true spectrum, each with its own evidence stage named above: natural-neurogenesis support and plasticity-based repair (grounded today); glial and myelin regeneration (early human trials, e.g. CCMR-Two); and the deep frontier of in-place cell reprogramming (guiding the brain’s own cells to become neurons), direct cell reprogramming, circuit reconstruction, and regenerative biomaterials (lab and earliest human studies). We name who is doing each, and label its stage honestly.
The brain makes some new neurons Clinical
Human dentate-gyrus studies indicate new-neuron formation persists into the 10th decade, impaired in Alzheimer’s — real, but limited and debated for three decades.
The brain’s own repair can be driven Frontier
The brain’s own regenerative routes — new neuron formation, plasticity, and support-cell renewal — can be supported and amplified, the foundation of zero-harm regeneration.
Glia can become neurons Frontier
Direct reprogramming guides glial cells to become neurons in place, using the brain’s own cells — a striking lab advance, not yet a human therapy.
Myelin repair reached people Clinical
CCMR-Two (ECTRIMS 2025) showed myelin repair can be promoted in people with MS — early human evidence on support-cell regeneration.
Integration is the hard problem Frontier
Newly formed neurons often fail to integrate into working circuits, and glial scars can impede repair — the central, honest challenge of the field.
Plasticity already restores function Demonstrated — clinical
Even without new cells, the brain rewires to recover function — the established basis of recovery after injury.
The honest challenges: this is the hardest problem in the Healthy pillar, and most of it is frontier. The adult brain’s natural regeneration is limited and even its extent is debated. Newly formed or reprogrammed neurons often fail to integrate into working circuits, and glial scars can impede repair — and much of this remains early laboratory science. We never present lab promise as clinical reality, and the most powerful tool today remains preventing loss. But the direction is unmistakable: across many converging pathways — each with real researchers and trials behind it — the oldest rule in neurology is being slowly, honestly rewritten.
The future, fully built
A future where the brain can regrow what it loses: natural neurogenesis supported, plasticity harnessed, synapses and support cells rebuilt, and — as the frontier matures — neurons regenerated, reprogrammed, and integrated into working circuits with the help of guiding scaffolds. Brain loss becomes, pathway by honest pathway, something we can begin to reverse rather than only prevent.
The proof, for this capability
Cited as evidence the capability is real, not as partners or endorsers.
Adult human neurogenesisClinical (contested)
Human dentate-gyrus studies (Journal of Neuroscience) found new-neuron formation persisting into the 10th decade, impaired in Alzheimer’s; extent debated for three decades.
The neurogenic nicheClinical
A 2025 review (Simard, Matosin & Mechawar) maps the niche debate and the sequencing methods now used to measure it.
Plasticity-based recoveryDemonstrated (clinical)
The brain rewires surviving circuits to recover function even where neurons are not replaced — established rehabilitation/neuroplasticity science.
Glial & myelin regenerationClinical (early)
The Cambridge Centre for Myelin Repair’s CCMR-Two study (ECTRIMS 2025, 67 people with MS) showed that myelin repair can be promoted in living people.
Cell reprogrammingFrontier
Direct lineage reprogramming guides glia to become neurons in place via neuron-defining transcription factors, using the brain’s own cells; active lab frontier.
Circuit integrationFrontier
Newly formed neurons often fail to integrate and reconstruct circuits, and glial scars can impede repair — the central challenge.
Regenerative biomaterialsFrontier
Scaffolds and 3D-bioprinted matrices guide the brain’s regenerating cells across damaged tissue in regenerative bioengineering research; preclinical to earliest research.
Functional recovery benchmarkFrontier
Preclinical human-NSC work showed locomotor recovery through remyelination and synaptic integration across a lesion — the functional readout that defines success.
Prevention is still primaryDemonstrated (clinical)
The Lancet Commission (2024) shows preventing loss remains the most powerful available tool while regeneration matures.
Honest framing
Real organizations, trials, and findings are cited as evidence the capability is real — not as partners or endorsers. The brain cannot meaningfully regrow itself in people today; most neuron- and circuit-level regeneration is frontier, and we label it frontier. Prevention remains the most powerful tool we have now.
Help build this future
Every signature grows the movement to make brain regeneration real — and free at the point of need.